AbbVie
ABBV
1,763 hedge funds and large institutions have $80.1B invested in AbbVie in 2017 Q2 according to their latest regulatory filings, with 116 funds opening new positions, 658 increasing their positions, 728 reducing their positions, and 62 closing their positions.
87% more first-time investments, than exits
New positions opened: 116 | Existing positions closed: 62
42% more funds holding in top 10
Funds holding in top 10: 83 → 118 (+35)
18% more call options, than puts
Call options by funds: $1.05B | Put options by funds: $888M
12% more capital invested
Capital invested by funds: $71.3B → $80.1B (+$8.83B)
2% more funds holding
Funds holding: 1,727 → 1,763 (+36)
0.77% more ownership
Funds ownership: 68.64% → 69.41% (+0.77%)
10% less repeat investments, than reductions
Existing positions increased: 658 | Existing positions reduced: 728
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$249M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$245M |
| 3 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$225M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$143M |
| 5 |
BlackRock
New York
|
+$125M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$213M |
| 2 |
State Street
Boston,
Massachusetts
|
-$105M |
| 3 |
Two Sigma Investments
New York
|
-$81.1M |
| 4 |
GCM
Glenview Capital Management
New York
|
-$80.1M |
| 5 |
Bank of New York Mellon
New York
|
-$72.3M |
ABBV Hedge Fund Activity: Q2 2017 in Review
1,763 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2017, worth a combined $80.1B — up 12% from $71.3B a quarter earlier.
Buyers outnumbered sellers: 116 funds opened new ABBV positions and 62 closed out — a net gain of 54 holders — while 658 added to existing stakes and 728 trimmed.
The largest buyer was Vanguard Group, adding an estimated $249M. The largest seller was Morgan Stanley, cutting an estimated $213M.
- 1,763 institutional investors held AbbVie (ABBV) as of Q2 2017, up from 1,727 in Q1 2017.
- Funds reported $80.1B of AbbVie stock for Q2 2017, up 12% quarter-over-quarter.
- 116 funds opened new AbbVie positions in Q2 2017 and 62 closed out, a net change of +54 holders.
- The largest AbbVie buyer in Q2 2017 was Vanguard Group, an estimated $249M added.
- The largest AbbVie seller in Q2 2017 was Morgan Stanley, an estimated $213M sold.
Based on aggregated 13F filings for Q2 2017.